言語を選択

HLA-A*0201 & B2M & MAGE-A4 (KVLEHVVRV)

HLA-A*0201 & B2M & MAGE-A4 (KVLEHVVRV) 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
His Tag & Avi Tag (1)His Tag (1)
マーカー
Biotin-labeled (1)PE Labeled (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
HLP-H82E5	Human	HEK293	Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Complex Protein (Monomer, MALS verified)
HLP-HP2H3	Human	HEK293	PE-Labeled Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Tetramer Protein

総数量2

HLA-A*0201 & B2M & MAGE-A4 (KVLEHVVRV)バックグランド

The MAGE A4 antigen is a cancer-testis antigen and is expressed intracellularly in various solid tumor tissues, MAGE peptide (KVLEHVVRV) is a cytotoxic T lymphocyte (CTL) epitope presented by HLA-A2 The Human HLA-A*0201. MAGE-A4 (KVLEHVVRV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and KVLEHVVRV peptide of the MAGE-A4.

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Ecopipam	PSYRX-101; Sch-39166	Phase 3 Clinical	Merck Sharp & Dohme Corp	Language Disorders; Speech Disorders; Self-Injurious Behavior; Lesch-Nyhan Syndrome; Childhood-Onset Fluency Disorder; Tourette Syndrome; Gambling; Stuttering	詳細
Tavapadon	CVL-751; PF-6649751; PF-06649751	Phase 3 Clinical	Pfizer Inc, Cerevel Therapeutics Llc	Kidney Diseases; Parkinson Disease; Hepatic Insufficiency	詳細
Thioridazine	TP-21	Phase 3 Clinical	Novartis Pharma Ag	Schizophrenia; Anxiety Disorders; Carcinoma, Hepatocellular	詳細
Olanzapine long acting injectable (Teva Pharmaceutical Industries)	TV-44749; TEV-‘749; mdc-TJK	Phase 3 Clinical	Medincell SA	Schizophrenia	詳細
PF-06412562	PF-6412562; PF-06412562	Phase 2 Clinical	Pfizer Inc	Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Parkinson Disease	詳細
Mevidalen	LY-3154207	Phase 2 Clinical	Eli Lilly And Company	Parkinson Disease; Lewy Body Disease	詳細
TGOF02N	TGOF-02N; TGOF02N; FKF02SC	Phase 2 Clinical	Fabre-Kramer	Schizophrenia	詳細
ASP-4345	ASP-4345	Phase 2 Clinical	Astellas Pharma Inc	Schizophrenia	詳細
Docarpamine (Martin Pharmaceuticals)		Phase 2 Clinical	Martin Pharmaceuticals Inc	Gastrointestinal Diseases; Liver Cirrhosis; Mouth Diseases	詳細
CVL-871	CVL-871	Phase 2 Clinical	Pfizer Inc	Dementia	詳細
[11C]NNC-112	[11C]NNC-112	Phase 2 Clinical	Glaxosmithkline Plc	Diagnostic agents	詳細
Lu-AF-28996		Phase 1 Clinical	H. Lundbeck A/S	Parkinson Disease	詳細
Olanzapine intranasal (Neurelis)	NRL-4; NRL-1004	Phase 1 Clinical	Neurelis Inc	Bipolar Disorder	詳細
Oxytocin/Methylergometrine Maleate		Phase 1 Clinical	Nanjing Gritpharma Co Ltd	Hemorrhage; Obstetric Labor Complications	詳細
ITI-333	ITI-333	Phase 1 Clinical	Intra-Cellular Therapies Inc	Mood Disorders; Pain; Opioid-Related Disorders	詳細
PF-06730110	PF-06730110; [18F]MNI-968	Phase 1 Clinical	Invicro Llc	Nerve Degeneration	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Docarpamine	TA-870; TA-8704	Approved		Tanadopa		Heart Failure	null	1994-01-01	Heart Failure	詳細
Olanzapine/Fluoxetine hydrochloride	OFC	Approved	Eli Lilly And Company	Symbyax	United States	Bipolar Disorder	Eli Lilly And Company	2003-12-24	Depressive Disorder, Major; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Treatment-Resistant	詳細
Zuclopenthixol Hydrochloride	LU-0108	Approved		Clopixol		Bipolar Disorder; Schizophrenia	null	1962-01-01	Schizophrenia; Bipolar Disorder	詳細
Methylergometrine Maleate		Approved		Metenarin, Methergine, Ryegonivin, Basofortina, Methylergobrevin					Postpartum Hemorrhage; Uterine Cervical Incompetence; Uterine Hemorrhage; Uterine Inertia	詳細
Samidorphan/Olanzapine	ALKS-3831	Approved	Alkermes Plc	Lybalvi	United States	Bipolar Disorder; Schizophrenia	Alkermes Inc	2021-05-28	Schizophrenia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Alcoholism	詳細
Olanzapine	LY-170053; INP-105; TEV-‘749; LY-170052; ALKS-7921	Approved	Eli Lilly And Company	Zyprexa Relprevv, Olansek, Zyprexa Zydis, Olanzapine ODF, 再普乐, Midax, Lanzac, Zyprexa, Zypadhera, Zalasta, Zyprexa Velotab	EU	Schizophrenia; Bipolar Disorder	null	1996-09-27	Opioid-Related Disorders; Chemotherapy-induced nausea and vomiting; Fasting; Anorexia Nervosa; Borderline Personality Disorder; Depressive Disorder, Treatment-Resistant; Gambling; Nausea; Vomiting; Postoperative Nausea and Vomiting; Emergence Delirium; Feeding and Eating Disorders; Malaria, Falciparum; Autistic Disorder; Hematologic Neoplasms; Neoplasms; Insulin Resistance; Anorexia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Depression; Stomach Neoplasms; Depressive Disorder, Major; Schizophrenia; Substance-Related Disorders; Weight Loss; Solid tumours	詳細
Phenylpropanolamine Hydrochloride		Approved		Nasadec, Nasathera, Pararhinol					Nasal Obstruction	詳細
Fenoldopam Mesylate	SKF-82526; SKF-82526J; (±)-SKF-82526	Approved	Abbott Laboratories	Corlopam	United States	Hypertension	Hospira Inc	1997-09-23	Hypertension	詳細
Olanzapine/Hydroxyzine pamoate		Approved							Nausea	詳細
Stepholidine		Approved			Mainland China	Headache; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome; Migraine Disorders	null	1995-01-01	Headache; Migraine Disorders; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome	詳細